GLP-1激动剂对初级预防10年心血管风险降低的影响:一个44周的开放标签前性研究

José Seijas-Amigo¹, Ángel Salgado-Barreira², Rosana Castelo-Dominguez³

¹Cardiology Department. Complejo Hospitalario Universidad de Santiago de Compostela, University of Santiago de Compostela, Spain; Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Universidade de Santiago de Compostela, Spain.

Diabetes & metabolic syndrome

|October 23, 2025

概括

葡萄糖类-1 (GLP-1) 受体激活剂显著降低了10年心血管风险,并改善了2型糖尿病患者的代谢控制. 建议在高风险人群中提前使用.

科学领域:

心脏病学和内分泌学.
对代谢疾病的药理干预措施

背景情况:

2型糖尿病 (T2DM) 与心血管风险增加有关.
初级预防策略对于管理T2DM患者心血管风险至关重要.

研究的目的:

评估葡萄糖类-1 (GLP-1) 受体激活剂对10年心血管风险 (CVR) 在T2DM患者的初级预防队列中的影响.
评估GLP-1受体激动剂对减肥,HbA1c,禁食血葡萄糖和脂质概况的影响.

主要方法:

这是一项为期44周的前性非随机研究,涉及135名2型糖尿病和肥胖患者.
在基线和第44周使用AHA ASCVD风险估计器Plus工具估计了10年CVR.
患者接受了各种GLP-1受体激动剂,包括皮下血红,口服血红和杜拉格卢.

主要成果:

在初级预防队列 (n=105) 中,平均10年CVR显著降低3.28个百分点 (13.45%的相对降低,p <0.001).
皮下注射的塞马格卢提德 (semaglutide) 减轻了最多的体重 (-8.1公斤),其次是口服的塞马格卢提德 (-6.5公斤) 和杜拉格卢提德 (-5.6公斤).
在HbA1c (8.1%至6.6%) 和空腹血葡萄糖 (-45.8 mg/dL) 中观察到显著改善,两者均为p < 0.001.

结论:

GLP-1受体激动剂有效地降低了接受初级预防的T2DM患者的10年心血管风险.
这些药物在改善代谢控制方面具有显著的益处,包括减肥,HbA1c和禁食血葡萄糖水平.
这些发现支持在高风险T2DM患者中考虑早期启动GLP-1受体激动剂.

关键词:

心血管疾病的风险.作为GLP-1受体的激动剂.主要预防主要预防.2 型糖尿病 2 型糖尿病减肥的方法减肥的方法减肥的方法

相关概念视频

01:24

Glucagon-like Receptor Agonists

840

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

840

01:23

Dipeptidyl Peptidase 4 Inhibitors

581

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

581

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

582

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

582

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

522

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

522

01:06

Oral Hypoglycemic Agents: Glinides

595

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

595

01:26

Atherosclerosis III: Management

319

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

319